The DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Metrics other than potency reveal systematic variation in responses to cancer drugs
Open accessAbstract
Large-scale analysis of cellular response to anti-cancer drugs typically focuses on variation in potency (IC50) assuming that it is the most important difference between effective/ineffective drugs or sensitive/resistant cells. We took a multi-parametric approach involving analysis of the slope of the dose-response curve (HS), the area under the curve (AUC) and the maximum effect (Emax). We found that some of these parameters vary systematically with cell line and others with drug class. For cell-cycle inhibitors, Emax often but not always correlated with cell proliferation rate. For drugs targeting the Akt/PI3K/mTOR pathway dose-response curves were unusually shallow. Classical pharmacology has no ready explanation for this phenomenon but single-cell analysis showed that it correlated with significant and heritable cell-to-cell variability in the extent of target inhibition. We conclude that parameters other than potency should be considered in the comparative analysis of drug response, particularly at clinically relevant concentrations near and above IC50.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Elements of Information Theory
Cover, T. M., & Thomas, J. A. (2001) · Wiley eBooks · doi:10.1002/0471200611 · Cited by 36,808
A Simple Sequentially Rejective Multiple Test Procedure
(1979) · Scandinavian Journal of Statistics · doi:10.2307/4615733 · Cited by 21,526
Goodall, C. (1988) · Technometrics · doi:10.1080/00401706.1988.10488412 · Cited by 8,675
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
Barretina, J., Caponigro, G., Stransky, N., Venkatesan, K., Margolin, A. A., Kim, S., Wilson, C. J., Lehár, J., Kryukov, G. V., Sonkin, D., et al. (2012) · Nature · doi:10.1038/nature11003 · Cited by 7,950
Sherr, C. J. (1996) · Science · doi:10.1126/science.274.5293.1672 · Cited by 5,379
The NCI60 human tumour cell line anticancer drug screen
Shoemaker, R. H. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1951 · Cited by 2,620
Systematic identification of genomic markers of drug sensitivity in cancer cells
Garnett, M. J., Edelman, E. J., Heidorn, S. J., Greenman, C. D., Dastur, A., Lau, K. W., Greninger, P., Thompson, I. R., Luo, X., Soares, J., et al. (2012) · Nature · doi:10.1038/nature11005 · Cited by 2,456
Cyclin is degraded by the ubiquitin pathway
Glotzer, M., Murray, A. W., & Kirschner, M. W. (1991) · Nature · doi:10.1038/349132a0 · Cited by 2,357
The possible effects of the aggregation of the molecules of haemoglobin on its dissociation curves
Hill, A. V., Hill, A. L., & Hill, A. V. (1910) · The Journal of Physiology · Cited by 2,181
Predicting new molecular targets for known drugs
Keiser, M. J., Setola, V., Irwin, J. J., Laggner, C., Abbas, A. I., Hufeisen, S. J., Jensen, N. H., Kuijer, M. B., Matos, R. C., Tran, T. B., et al. (2009) · Nature · doi:10.1038/nature08506 · Cited by 1,667
BRAF mutation predicts sensitivity to MEK inhibition
Solit, D. B., Garraway, L. A., Pratilas, C. A., Sawai, A., Getz, G., Basso, A., Ye, Q., Lobo, J. M., She, Y., Osman, I., et al. (2006) · Nature · doi:10.1038/nature04304 · Cited by 1,328
Holford, N. H. G., & Sheiner, L. B. (1981) · Clinical Pharmacokinetics · doi:10.2165/00003088-198106060-00002 · Cited by 1,143
Active-Site Inhibitors of mTOR Target Rapamycin-Resistant Outputs of mTORC1 and mTORC2
Feldman, M. E., Apsel, B., Uotila, A., Loewith, R., Knight, Z. A., Ruggero, D., & Shokat, K. M. (2009) · PLoS Biology · doi:10.1371/journal.pbio.1000038 · Cited by 1,082
Non-genetic origins of cell-to-cell variability in TRAIL-induced apoptosis
Spencer, S. L., Gaudet, S., Albeck, J. G., Burke, J. M., & Sorger, P. K. (2009) · Nature · doi:10.1038/nature08012 · Cited by 1,021
Self-citationThe Hill equation revisited: uses and misuses
Weiss, J. N. (1997) · The FASEB Journal · doi:10.1096/fasebj.11.11.9285481 · Cited by 1,000
Large-scale prediction and testing of drug activity on side-effect targets
Lounkine, E., Keiser, M. J., Whitebread, S., Mikhailov, D., Hamon, J., Jenkins, J. L., Lavan, P., Weber, E., Doak, A. K., Côté, S., et al. (2012) · Nature · doi:10.1038/nature11159 · Cited by 881
Chemosensitivity prediction by transcriptional profiling
Staunton, J. E., Slonim, D. K., Coller, H. A., Tamayo, P., Angelo, M. J., Park, J., Scherf, U., Lee, J. K., Reinhold, W. O., Weinstein, J. N., et al. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.191368598 · Cited by 684
Dynamic Proteomics of Individual Cancer Cells in Response to a Drug
Cohen, A. A., Geva-Zatorsky, N., Eden, E., Frenkel-Morgenstern, M., Issaeva, I., Sigal, A., Milo, R., Cohen-Saidon, C., Liron, Y., Kam, Z., et al. (2008) · Science · doi:10.1126/science.1160165 · Cited by 596
Variability and memory of protein levels in human cells
Sigal, A., Milo, R., Cohen, A., Geva-Zatorsky, N., Klein, Y., Liron, Y., Rosenfeld, N., Danon, T., Perzov, N., & Alon, U. (2006) · Nature · doi:10.1038/nature05316 · Cited by 587
Subtype and pathway specific responses to anticancer compounds in breast cancer
Heiser, L. M., Sadanandam, A., Kuo, W.-L., Benz, S. C., Goldstein, T. C., Ng, S., Gibb, W. J., Wang, N. J., Ziyad, S., Tong, F., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018854108 · Cited by 475
Self-citationHsieh, A. C., Costa, M., Zollo, O., Davis, C., Feldman, M. E., Testa, J. R., Meyuhas, O., Shokat, K. M., & Ruggero, D. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.01.021 · Cited by 434
mTOR signaling and drug development in cancer
Dancey, J. (2010) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2010.21 · Cited by 417
The proliferation rate paradox in antimitotic chemotherapy
Mitchison, T. J. (2012) · Molecular Biology of the Cell · doi:10.1091/mbc.e10-04-0335 · Cited by 363
Derivation and properties of Michaelis-Menten type and Hill type equations for reference ligands
Chou, T.-C. (1976) · Journal of Theoretical Biology · doi:10.1016/0022-5193(76)90169-7 · Cited by 349
Variability and Robustness in T Cell Activation from Regulated Heterogeneity in Protein Levels
Feinerman, O., Veiga, J., Dorfman, J. R., Germain, R. N., & Altan-Bonnet, G. (2008) · Science · doi:10.1126/science.1158013 · Cited by 338
Dose-response curve slope sets class-specific limits on inhibitory potential of anti-HIV drugs
Shen, L., Peterson, S., Sedaghat, A. R., McMahon, M. A., Callender, M., Zhang, H., Zhou, Y., Pitt, E., Anderson, K. S., Acosta, E. P., et al. (2008) · Nature Medicine · doi:10.1038/nm1777 · Cited by 327
Aligue, R., Akhavan‐Niak, H., & Russell, P. (1994) · The EMBO Journal · doi:10.1002/j.1460-2075.1994.tb06956.x · Cited by 261
Predicting drug susceptibility of non–small cell lung cancers based on genetic lesions
Sos, M. L., Michel, K., Zander, T., Weiss, J., Frommolt, P., Peifer, M., Li, D., Ullrich, R., Koker, M., Fischer, F., et al. (2009) · Journal of Clinical Investigation · doi:10.1172/jci37127 · Cited by 258
Application of the mutual information criterion for feature selection in computer‐aided diagnosis
Tourassi, G. D., Frederick, E. D., Markey, M. K., & Floyd, C. E. (2001) · Medical Physics · doi:10.1118/1.1418724 · Cited by 221
Bazzaro, M., Lee, M. K., Zoso, A., Stirling, W. L. H., Santillan, A., Shih, I., & Roden, R. B. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2321 · Cited by 160
Molecular Target Class Is Predictive of In vitro Response Profile
Greshock, J. D., Bachman, K. E., Degenhardt, Y., Jing, J., Wen, Y. H., Eastman, S. D., McNeil, E., Moy, C. H., Wegrzyn, R. J., Auger, K. R., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3788 · Cited by 124
Dose–response curve slope is a missing dimension in the analysis of HIV-1 drug resistance
Sampah, M. E., Shen, L., Jilek, B. L., & Siliciano, R. F. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1018360108 · Cited by 111
Fractional proliferation: a method to deconvolve cell population dynamics from single-cell data
Tyson, D. R., Garbett, S. P., Frick, P. L., & Quaranta, V. (2012) · Nature Methods · doi:10.1038/nmeth.2138 · Cited by 102
Gaudet, S., Spencer, S. L., Chen, W. W., & Sorger, P. K. (2012) · PLoS Computational Biology · doi:10.1371/journal.pcbi.1002482 · Cited by 95
Self-citationAdaptive informatics for multifactorial and high-content biological data
Millard, B. L., Niepel, M., Menden, M. P., Muhlich, J. L., & Sorger, P. K. (2011) · Nature Methods · doi:10.1038/nmeth.1600 · Cited by 65
Self-citationPhase I trials of targeted anticancer drugs: a need to refocus
Borden, E. C., & Dowlati, A. (2012) · Nature Reviews Drug Discovery · doi:10.1038/nrd3909 · Cited by 8
Cited by
A community effort to assess and improve drug sensitivity prediction algorithms
Community, N. D., Costello, J. C., Heiser, L. M., Georgii, E., Gönen, M., Menden, M. P., Wang, N. J., Bansal, M., Ammad-ud-din, M., Hintsanen, P., et al. (2014) · Nature Biotechnology · doi:10.1038/nbt.2877 · Cited by 772
Self-citationGrowth rate inhibition metrics correct for confounders in measuring sensitivity to cancer drugs
Hafner, M., Niepel, M., Chung, M., & Sorger, P. K. (2016) · Nature Methods · doi:10.1038/nmeth.3853 · Cited by 681
Self-citationDiverse drug-resistance mechanisms can emerge from drug-tolerant cancer persister cells
Ramirez, M., Rajaram, S., Steininger, R. J., Osipchuk, D., Roth, M. A., Morinishi, L. S., Evans, L., Ji, W., Hsu, C.-H., Thurley, K., et al. (2016) · Nature Communications · doi:10.1038/ncomms10690 · Cited by 581
Highly multiplexed imaging of single cells using a high-throughput cyclic immunofluorescence method
Lin, J.-R., Fallahi-Sichani, M., & Sorger, P. K. (2015) · Nature Communications · doi:10.1038/ncomms9390 · Cited by 562
Self-citationYadav, B., Pemovska, T., Szwajda, A., Kulesskiy, E., Kontro, M., Karjalainen, R., Majumder, M. M., Malani, D., Murumägi, A., Knowles, J., et al. (2014) · Scientific Reports · doi:10.1038/srep05193 · Cited by 359
Metadata
- Authors
- Fallahi-Sichani, M., Honarnejad, S., Heiser, L. M., Gray, J. W., & Sorger, P. K.
- Venue
- Nature Chemical Biology
- Published
- 2013-09-08
- Volume
- 9
- Issue
- 11
- Pages
- 708-714
- ISSN
- 1552-4450 (ISSN-L)
- 1552-4469
- OpenAlex
- W2078448804
- Cited by
- 314
- References
- 37
- FWCI
- 26.91
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.